Bergen 30 May 2023: Reference is made to the stock exchange announcement
published by BerGenBio ASA (the "Company") earlier today, 30 May 2023, regarding
the commencement of the subscription period in the rights issue (the "Rights
Issue"). As part of this process, subscription rights have been allocated to
primary insiders and their close associates.

Martin Olin, CEO of BerGenBio ASA, has on 30 May 2023 acquired 1 046 125
subscription rights in BerGenBio ASA with no price payable.

Anders Tullgren, Chairman of the Board of Directors of BerGenBio ASA, has on 30
May 2023 acquired 1 409 872 subscription rights in BerGenBio ASA with no price
payable.

Sveinung Hole, Member of the Board of Directors of BerGenBio ASA, has on 30 May
2023 acquired 83 182 subscription rights in BerGenBio ASA with no price payable.

Svev AS, a company closely associated to Sveinung Hole, Member of the Board of
Directors of BerGenBio ASA, has on 30 May 2023 acquired 2 945 053 subscription
rights in BerGenBio ASA with no price payable.

Sarsia Seed AS, a company closely associated to Sveinung Hole, Member of the
Board of Directors of BerGenBio ASA, has on 30 May 2023 acquired 59 719 358
subscription rights in BerGenBio ASA with no price payable.

Sarsia Development AS, a company closely associated to Sveinung Hole, Member of
the Board of Directors of BerGenBio ASA, has on 30 May 2023 acquired 33 131 992
subscription rights in BerGenBio ASA with no price payable.

Please see the attached notifications of trade for information regarding the
primary insiders' and their close associates' receipt of subscription rights in
the Rights Issue.

This information is subject to the disclosure requirements pursuant to article
19 of the EU Market Abuse Regulation and section 5-12 of the Norwegian
Securities Trading Act.